Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression

被引:33
|
作者
Vigneswaran, Nadarajah [1 ]
Baucum, Darryl C.
Wu, Jean
Lou, Yahuan
Bouquot, Jerry
Muller, Susan
Zacharias, Wolfgang
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Diagnost Sci, Dent Branch, Houston, TX 77030 USA
[2] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA
[4] Univ Louisville, James Graham Brown Canc Ctr, Dept Med, Louisville, KY 40202 USA
[5] Univ Louisville, James Graham Brown Canc Ctr, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA
关键词
D O I
10.1186/1471-2407-7-108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation and progression. Methods: DNA microarray, immunoblotting and immunohistochemical analyses were used to examine the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM, OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes (TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry. Results: Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1 but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa. Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part, on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression in primary OSCC correlated significantly with larger tumor size. There was no significant association between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells and TIL. Conclusion: Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or metastatic progression.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression
    Nadarajah Vigneswaran
    Darryl C Baucum
    Jean Wu
    Yahuan Lou
    Jerry Bouquot
    Susan Muller
    Wolfgang Zacharias
    BMC Cancer, 7
  • [2] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) during liver regeneration
    Yamaguchi, Y
    Shiraki, K
    Saitou, Y
    Nakano, T
    Mizuno, S
    Uemoto, S
    JOURNAL OF HEPATOLOGY, 2004, 40 (04) : 718 - 719
  • [3] Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
    Macher-Goeppinger, Stephan
    Aulmann, Sebastian
    Tagscherer, Katrin E.
    Wagener, Nina
    Haferkamp, Axel
    Penzel, Roland
    Brauckhoff, Antje
    Hohenfellner, Markus
    Sykora, Jaromir
    Walczak, Henning
    Teh, Bin T.
    Autschbach, Frank
    Herpel, Esther
    Schirmacher, Peter
    Roth, Wilfried
    CLINICAL CANCER RESEARCH, 2009, 15 (02) : 650 - 659
  • [4] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling
    Thorburn, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : 461 - 465
  • [5] The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis
    Michowitz, Y
    Goldstein, E
    Roth, A
    Afek, A
    Abashidze, A
    Ben Gal, Y
    Keren, G
    George, J
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (07) : 1018 - 1024
  • [6] Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
    Park, SY
    Billiar, TR
    Seol, DW
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (01) : 150 - 153
  • [7] Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Early Pregnancy
    Liu, Jian
    Lu, Huijuan
    Wang, Xiaowen
    Chen, Keming
    Lu, Jinzhi
    Yi, Cunjian
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2021, 43 (06): : 553 - 559
  • [8] Dammarenolic acid sensitizes cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
    Kroeger, A.
    Proksch, P.
    Kampkoetter, A.
    Waetjen, W.
    Kahl, R.
    Chovolou, Y.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 72 - 72
  • [9] The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?
    McGrath, Emmet E.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 983 - 987
  • [10] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
    Song, KM
    Chen, YG
    Göke, R
    Wilmen, A
    Seidel, C
    Göke, A
    Hilliard, B
    Chen, YH
    JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07): : 1095 - 1103